Carbamoylphosphate synthetase deficiency in an adult: deterioration due to administration of valproic acid.
A 24-year-old patient had symptoms of lethargy, convulsions and hyperammonaemia during valproic acid therapy. Cessation of valproic acid treatment brought about an improvement both of the symptoms and of the hyperammonaemia. However, enzymatic analysis after the cessation of valproic acid therapy revealed a complete absence of carbamoylphosphate synthetase (CPS) activity in liver biopsy. A unique polypeptide band, corresponding to the control CPS protein in molecular weight ('CPS-like' protein), was found in normal amounts in the patient's liver on sodium dodecyl sulphate-polyacrylamide gel electrophoresis. This CPS-like protein seemed to be more labile than the control, because the polypeptide band became faint after freeze-thawing. Intravenous administration of L-alanine resulted in a significant increase of serum urea and a transient increase of blood ammonia concentrations. These results strongly suggest that the patient has a labile CPS protein with no activity in vitro but some activity in vivo. We consider that valproic acid may have disrupted some metabolic adaptation by reducing N-acetylglutamate in the liver, which in combination with CPS deficiency induced severe hyperammonaemia.
Horiuchi
M
M
Department of Internal Medicine, Faculty of Medicine, Kogoshima University, Japan.
Imamura
Y
Y
Nakamura
N
N
Maruyama
I
I
Saheki
T
T
D000328:Adult; D000409:Alanine; D000641:Ammonia / Q000097:blood; D001806:Blood Urea Nitrogen; D002223:Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) / Q000172:deficiency*; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D014508:Urea / Q000378:metabolism; D014635:Valproic Acid / Q000009:adverse effects*
D014635:Valproic Acid; D000641:Ammonia; D014508:Urea; D002223:Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); D000409:Alanine